Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Meningitis, Cryptococcal | 3 | 2018 | 79 | 1.97 | Why? |
| AIDS-Related Opportunistic Infections | 2 | 2017 | 260 | 1.10 | Why? |
| Anti-Retroviral Agents | 2 | 2017 | 1099 | 0.73 | Why? |
| Vitamin A Deficiency | 1 | 2017 | 16 | 0.70 | Why? |
| Induction Chemotherapy | 1 | 2018 | 149 | 0.68 | Why? |
| Micronutrients | 1 | 2017 | 310 | 0.51 | Why? |
| Outpatients | 3 | 2021 | 3417 | 0.43 | Why? |
| Recovery of Function | 1 | 2020 | 2461 | 0.40 | Why? |
| HIV Infections | 4 | 2018 | 11620 | 0.37 | Why? |
| Malnutrition | 1 | 2017 | 932 | 0.34 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.34 | Why? |
| Health Resources | 1 | 2018 | 2592 | 0.28 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.28 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.27 | Why? |
| Vitamin D Deficiency | 1 | 2017 | 1782 | 0.26 | Why? |
| Tennessee | 2 | 2021 | 243 | 0.25 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.25 | Why? |
| United States | 14 | 2021 | 46150 | 0.23 | Why? |
| Observation | 1 | 2021 | 80 | 0.22 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.22 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.21 | Why? |
| Immunocompromised Host | 1 | 2017 | 5150 | 0.20 | Why? |
| Flucytosine | 1 | 2018 | 12 | 0.19 | Why? |
| Acetazolamide | 1 | 2018 | 27 | 0.19 | Why? |
| Vaccines, Synthetic | 2 | 2021 | 3231 | 0.18 | Why? |
| Botswana | 1 | 2017 | 98 | 0.17 | Why? |
| Work | 1 | 2020 | 342 | 0.17 | Why? |
| Fluconazole | 1 | 2018 | 145 | 0.17 | Why? |
| Intracranial Hypertension | 1 | 2018 | 111 | 0.16 | Why? |
| Personnel, Hospital | 2 | 2020 | 2273 | 0.16 | Why? |
| Amphotericin B | 1 | 2018 | 256 | 0.16 | Why? |
| Risk-Taking | 1 | 2021 | 508 | 0.16 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.16 | Why? |
| Systemic Inflammatory Response Syndrome | 3 | 2021 | 6653 | 0.16 | Why? |
| Network Meta-Analysis | 1 | 2018 | 426 | 0.15 | Why? |
| Syndrome | 1 | 2020 | 1310 | 0.15 | Why? |
| Adult | 16 | 2021 | 244371 | 0.14 | Why? |
| Delivery of Health Care | 2 | 2021 | 15909 | 0.14 | Why? |
| Telecommunications | 1 | 2020 | 551 | 0.14 | Why? |
| Fungi | 1 | 2017 | 471 | 0.13 | Why? |
| Invasive Fungal Infections | 1 | 2017 | 274 | 0.13 | Why? |
| Vaping | 1 | 2019 | 436 | 0.12 | Why? |
| Adolescent | 11 | 2021 | 86841 | 0.12 | Why? |
| Electronic Nicotine Delivery Systems | 1 | 2019 | 561 | 0.11 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.11 | Why? |
| Male | 17 | 2021 | 367725 | 0.11 | Why? |
| Vaccination Coverage | 1 | 2021 | 1249 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.11 | Why? |
| Female | 17 | 2021 | 380317 | 0.11 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.11 | Why? |
| Academic Medical Centers | 2 | 2020 | 3088 | 0.11 | Why? |
| Lung Injury | 1 | 2019 | 919 | 0.10 | Why? |
| Humans | 25 | 2021 | 930598 | 0.10 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.10 | Why? |
| Young Adult | 8 | 2021 | 93724 | 0.10 | Why? |
| Environmental Exposure | 1 | 2020 | 1558 | 0.10 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.10 | Why? |
| Odds Ratio | 1 | 2021 | 5861 | 0.09 | Why? |
| Middle Aged | 11 | 2021 | 270681 | 0.09 | Why? |
| Community-Acquired Infections | 1 | 2020 | 2328 | 0.09 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.08 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.08 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.08 | Why? |
| Treatment Outcome | 3 | 2021 | 51732 | 0.07 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.07 | Why? |
| Aged | 5 | 2021 | 215776 | 0.07 | Why? |
| Child, Preschool | 4 | 2021 | 36283 | 0.06 | Why? |
| Socioeconomic Factors | 1 | 2020 | 8495 | 0.06 | Why? |
| Developing Countries | 1 | 2018 | 4283 | 0.06 | Why? |
| Nervous System Diseases | 1 | 2021 | 4092 | 0.06 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.06 | Why? |
| Seroepidemiologic Studies | 3 | 2021 | 10017 | 0.05 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.05 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.05 | Why? |
| Child | 5 | 2021 | 70012 | 0.05 | Why? |
| Quality of Life | 1 | 2021 | 9820 | 0.05 | Why? |
| Antibodies, Viral | 3 | 2021 | 51949 | 0.05 | Why? |
| Dronabinol | 1 | 2019 | 89 | 0.05 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.05 | Why? |
| Ambulatory Care Facilities | 2 | 2020 | 2063 | 0.05 | Why? |
| Infant | 2 | 2020 | 30274 | 0.04 | Why? |
| Illinois | 1 | 2019 | 468 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2021 | 9044 | 0.04 | Why? |
| Wisconsin | 1 | 2019 | 607 | 0.04 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.04 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.04 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.04 | Why? |
| Prospective Studies | 2 | 2020 | 43301 | 0.04 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.04 | Why? |
| Intensive Care Units, Pediatric | 1 | 2021 | 1098 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Regression Analysis | 1 | 2021 | 2484 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.03 | Why? |
| Retrospective Studies | 3 | 2021 | 105322 | 0.03 | Why? |
| Health Facilities | 1 | 2021 | 1230 | 0.03 | Why? |
| Case-Control Studies | 2 | 2021 | 17671 | 0.03 | Why? |
| Immunomodulation | 1 | 2020 | 1472 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2019 | 27595 | 0.03 | Why? |
| Stroke Volume | 1 | 2021 | 2153 | 0.03 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.03 | Why? |
| Patient Care | 1 | 2021 | 1664 | 0.02 | Why? |
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 1645 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2020 | 2705 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2020 | 3444 | 0.02 | Why? |
| Aged, 80 and over | 1 | 2017 | 88759 | 0.02 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2021 | 7220 | 0.02 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.02 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.02 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Travel | 1 | 2020 | 7220 | 0.01 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.01 | Why? |
| Cross Infection | 1 | 2020 | 8675 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Cytokines | 1 | 2017 | 15010 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |